MARIMED INC. (MRMD) Form 8-K — Aug 12, 2026
MariMed reported record Q2 2026 revenue of $41.9 million, up from $39.5 million a year ago, which management called the highest quarterly revenue in company history. Wholesale revenue rose 6% and retail revenue rose 7% sequentially, with revenue up at 12 of 13 Thrive Dispensary locations. Profitability moved the other way: adjusted EBITDA fell to $3.9 million from $4.8 million (margin compressed to 9% from 12%), GAAP gross margin slipped to 38.7% from 40.3%, and the GAAP net loss widened to $3.6 million from $1.4 million. The company still generated $3.2 million of operating cash flow in the first half.
Key figures
- Revenue
- 41925000
- Revenue Yoy
- approximately 6% (Q2 2026 $41.9M vs Q2 2025 $39.5M, both figures stated in filing)
- Total Assets
- 197233000
- Cash Position
- 8437000
- Retail revenue q2 2026
- 23218000
- Six month revenue 2026
- 81406000
- Adjusted ebitda q2 2025
- 4787000
- Adjusted ebitda q2 2026
- 3948000
- Interest expense q2 2026
- 2007000
- Gaap gross margin q2 2025
- 40.3%
- Gaap gross margin q2 2026
- 38.7%
- Retail revenue seq growth
- 7%
- Wholesale revenue q2 2026
- 18514000
- Non gaap net income q2 2025
- 262000
- Operating cash flow h1 2026
- 3168000
- Wholesale revenue seq growth
- 6%
- Loyalty membership growth ytd
- 14%
- Adjusted ebitda margin q2 2025
- 12.1%
- Adjusted ebitda margin q2 2026
- 9.4%
- Retail transactions seq growth
- 7%
- Income taxes payable jun 30 2026
- 31547000
- Mortgages notes payable noncurrent
- 75399000
- New series b convertible preferred
- 6933000
- Provision for income taxes q2 2026
- 2018000
- Gain on debt extinguishment h1 2026
- 699000
- Brand distribution pct of storefronts
- 85%
- Thrive locations with seq revenue growth
- 12 of 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.